| __timestamp | MiMedx Group, Inc. | Wave Life Sciences Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 2999000 |
| Thursday, January 1, 2015 | 133384000 | 10393000 |
| Friday, January 1, 2016 | 179997000 | 15994000 |
| Sunday, January 1, 2017 | 220119000 | 26975000 |
| Monday, January 1, 2018 | 258528000 | 39509000 |
| Tuesday, January 1, 2019 | 198205000 | 48869000 |
| Wednesday, January 1, 2020 | 181022000 | 42510000 |
| Friday, January 1, 2021 | 198359000 | 46105000 |
| Saturday, January 1, 2022 | 208789000 | 50513000 |
| Sunday, January 1, 2023 | 211124000 | 51292000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, MiMedx Group, Inc. and Wave Life Sciences Ltd. have taken different paths in optimizing these costs. From 2014 to 2023, MiMedx's SG&A expenses have fluctuated, peaking in 2018 with a 40% increase from 2014, before stabilizing around 210 million USD in recent years. In contrast, Wave Life Sciences has shown a more consistent upward trend, with expenses growing by over 1,600% from 2014 to 2023, reaching approximately 51 million USD. This stark difference highlights MiMedx's ability to maintain a relatively stable SG&A cost structure, while Wave Life Sciences has expanded its operational footprint. Understanding these trends provides valuable insights into each company's strategic priorities and operational efficiencies.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing Sanofi and MiMedx Group, Inc.
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Jazz Pharmaceuticals plc vs MiMedx Group, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing SG&A Expenses: Alkermes plc vs MiMedx Group, Inc. Trends and Insights
Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights
Perrigo Company plc or MiMedx Group, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? MorphoSys AG or Wave Life Sciences Ltd.
Who Optimizes SG&A Costs Better? Catalyst Pharmaceuticals, Inc. or Wave Life Sciences Ltd.
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.